Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3811204 | 0.86 | L3MBTL1 (0.58) | ALOX15SMN1; SMN2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL11880986 | 0.85 | L3MBTL1 (0.56) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL8828412 | 0.83 | ALOX15 (0.59) | MEN1KMT2AALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL3813935 | 0.83 | L3MBTL1 (0.64) | L3MBTL1NPC1 | |
| SCHEMBL6317361 | 0.82 | NPC1 (0.72) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL17129733 | 0.82 | L3MBTL1 (0.62) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL7333688 | 0.82 | MAPT (0.59) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL13603757 | 0.82 | L3MBTL1 (0.54) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL339492 | 0.82 | ALOX15 (0.81) | MEN1KMT2AALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL11660630 | 0.81 | ALOX15 (0.57) | MEN1KMT2AALOX15SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441837-B2 | Immobilization of phenolic compounds | SPAGO NANOMEDICAL AB (SE) | 2025-10-14 | — | — | US | disclosed |
| CN-114829452-B | Immobilization of phenolic compounds | 斯帕果纳米医学有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230039790-A1 | Immobilization Of Phenolic Compounds | SPAGO NANOMEDICAL AB (SE) | 2023-02-09 | — | — | US | disclosed |
| EP-4077475-A1 | IMMOBILIZATION OF PHENOLIC COMPOUNDS | Spago Nanomedical AB (SE) | 2022-10-26 | — | — | EP | disclosed |
| CN-114829452-A | Immobilization of phenolic compounds | 斯帕果纳米医学有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021122859-A1 | IMMOBILIZATION OF PHENOLIC COMPOUNDS | SPAGO NANOMEDICAL AB (SE) | 2021-06-24 | — | — | WO | disclosed |
| EP-3838967-A1 | IMMOBILIZATION OF PHENOLIC COMPOUNDS | Spago Nanomedical AB (SE) | 2021-06-23 | — | — | EP | disclosed |
| CN-103610669-B | Di- (p-alkoxy benzene acrylketone) glutathione-S-transsulfurase latent inhibitor | 重庆医科大学 | 2018-03-27 | — | — | CN | disclosed |
| US-20170298051-A1 | ACTIVATOR OF ADIPONECTIN RECEPTOR | THE UNIVERSITY OF TOKYO (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20170298051-A1 | ACTIVATOR OF ADIPONECTIN RECEPTOR | THE UNIVERSITY OF TOKYO (JP) | 2017-10-19 | — | — | US | disclosed |
| EP-3053911-A1 | ADIPONECTIN RECEPTOR-ACTIVATING COMPOUND | The University of Tokyo (JP) | 2016-08-10 | — | — | EP | disclosed |
| US-20160214967-A1 | ACTIVATOR OF ADIPONECTIN RECEPTOR | THE UNIVERSITY OF TOKYO (JP) | 2016-07-28 | — | — | US | disclosed |
| US-20160214967-A1 | ACTIVATOR OF ADIPONECTIN RECEPTOR | THE UNIVERSITY OF TOKYO (JP) | 2016-07-28 | — | — | US | disclosed |
| CN-103610669-A | Di- (p-alkoxy benzene acrylketone) glutathione-S-transsulfurase latent inhibitor | UNIV CHONGQING MEDICAL | 2014-03-05 | — | — | CN | disclosed |
| US-6239220-B1 | Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. | 2001-05-29 | — | — | US | disclosed |
| WO-2000004062-A1 | RECOVERY OF TRIARYLMETHYL HALIDE PROTECTING GROUPS CLEAVED DURING OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | disclosed |
| US-5973188-A | Acetic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 1999-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214967-A1 | ACTIVATOR OF ADIPONECTIN RECEPTOR | ADIPOR1, ADIPOR2, CCKAR | MEN1 3820/4885KMT2A 2894/4885ALOX15 726/4885 |
| US-20170298051-A1 | ACTIVATOR OF ADIPONECTIN RECEPTOR | ADIPOR1, ADIPOR2, CCKAR | MEN1 3820/4885KMT2A 2894/4885ALOX15 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.